Bank Of New York Mellon Corp Relay Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$14.16 - $24.02 $5.5 Million - $9.33 Million	388,485 New	388,485 $5.8 Million
Q3 2022 Nov 14, 2022	BUY	$18.07 - $31.37 $806,572 - $1.4 Million	44,636 Added 15.0%	342,252 $7.66 Million
Q2 2022 Aug 15, 2022	BUY	$13.31 - $34.88 $142,816 - $374,262	10,730 Added 3.74%	297,616 $4.99 Million
Q1 2022 May 11, 2022	BUY	$20.26 - $32.36 $120,709 - $192,800	5,958 Added 2.12%	286,886 $8.59 Million
Q4 2021 Feb 11, 2022	BUY	$26.0 - $37.03 $1.2 Million - $1.71 Million	46,046 Added 19.6%	280,928 $8.63 Million
Q3 2021 Nov 12, 2021	BUY	$29.75 - $37.99 $2.01 Million - $2.56 Million	67,509 Added 40.33%	234,882 $7.41 Million
Q2 2021 Aug 11, 2021	BUY	$27.5 - $38.19 $783,970 - $1.09 Million	28,508 Added 20.53%	167,373 $6.12 Million
Q1 2021 May 13, 2021	BUY	$32.52 - $61.53 $748,317 - $1.42 Million	23,011 Added 19.86%	138,865 $4.8 Million
Q4 2020 Feb 09, 2021	BUY	$35.51 - $54.03 $951,703 - $1.45 Million	26,801 Added 30.1%	115,854 $4.81 Million
Q3 2020 Nov 12, 2020	BUY	$32.81 - $45.1 $2.92 Million - $4.02 Million	89,053 New	89,053 $3.79 Million

183

127M

1.7K

18K

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $780M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.